Variant of Uncertain Significance: How to Read a VUS Result
A variant of uncertain significance (VUS) is a DNA change for which available evidence is insufficient to classify it as pathogenic or benign. It is a statement about evidence, not a finding of disease or inherited risk.
Quick Answer
A variant of uncertain significance (VUS) is a DNA change for which available evidence is insufficient to classify it as pathogenic or benign. It is a statement about evidence, not a finding of disease or inherited risk.
An Evidence Classification
A VUS is neither a positive nor a negative result. Laboratories assess population data, computational evidence, functional studies and family information where available.
What Happens Next
Classifications can change as evidence accumulates. The testing laboratory and genetics professional are the appropriate sources for reclassification and personal follow-up.
Key Takeaways
- ·A VUS does not establish cancer risk.
- ·It should not be treated as a pathogenic finding.
- ·Keep the laboratory and report date for future review.
Put these genes in pathway context
Frequently asked questions
What is the key idea in Variant of Uncertain Significance: How to Read a VUS Result?
A variant of uncertain significance (VUS) is a DNA change for which available evidence is insufficient to classify it as pathogenic or benign. It is a statement about evidence, not a finding of disease or inherited risk.
What should be kept with the result or mechanism?
A VUS does not establish cancer risk. It should not be treated as a pathogenic finding. Keep the laboratory and report date for future review.
References
Continue Reading
Germline vs Somatic Testing: Two Different Cancer Questions
2 min read
BRCA1: Homologous Recombination, Inherited Risk and HRD
7 min read
RAD51C vs RAD51D: Inherited-Risk Evidence in Context
2 min read
TP53 and Li-Fraumeni Syndrome: Inherited-Risk Context
3 min read
Penetrance in Hereditary Cancer: Why a Variant Is Not a Diagnosis
3 min read
How to Read an Inherited-Cancer Genetic Testing Report
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
BRCA1 has 100+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.